LRRC15 antibody
- Known as:
- LRRC15 (anti-)
- Catalog number:
- orb101141
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- LRRC15 antibody
Related genes to: LRRC15 antibody
- Gene:
- LRRC15 NIH gene
- Name:
- leucine rich repeat containing 15
- Previous symbol:
- -
- Synonyms:
- LIB
- Chromosome:
- 3q29
- Locus Type:
- gene with protein product
- Date approved:
- 2003-04-25
- Date modifiied:
- 2015-08-27
Related products to: LRRC15 antibody
Related articles to: LRRC15 antibody
- The fourth Paediatric Therapeutic Development Workshop focused on osteosarcoma, the most common primary bone cancer in children and young adults. Current treatment of osteosarcoma comprises surgery and chemotherapy. Outcome has shown very little improvement over the last four decades and there are substantial unmet needs including improving survival, especially in metastatic or relapsed disease, and reducing treatment toxicity. There is a lack of new therapeutics in osteosarcoma, with the evaluation of new treatments challenged by complex biology and variation in chemotherapy standard of care regimens. An antibody-drug conjugate (ADC) targeting LRRC15 with an osteosarcoma-relevant payload is a promising therapeutic approach. Small molecule inhibitors and degraders targeting SMARCAL1 should be considered as a very high priority, as it is a target applicable to several high unmet need malignancies. Preclinical evaluation of KIF18A in osteosarcoma models is required. An early phase study of an eIF4A1 inhibitor is warranted. Further preclinical validation of RUNX2 using PROTACs or ADCs is required. Targeting MYC, either indirectly or directly is a high priority. Osteosarcomas have significant genomic instability and impaired DNA repair mechanisms and efforts are ongoing to exploit this vulnerability therapeutically. The goal is that these therapeutic developments will improve survival for patients with osteosarcoma. - Source: PubMed
Publication date: 2026/08/18
Baxter Joseph SMontiel Equihua ClaudiaMolenaar Jan JBerlanga PabloBishop Michael WBlanc PatriciaCampbell-Hewson QuentinCasanova MichelaCortes-Ciriano IsidroCrompton BrianDaems SamDanielson LauraDela Cruz FilemonFlanagan AdrienneGorlick RichardGraham AnnGuenther Lillian MHecker-Nolting StefanieHelman LeeKavanagh-Williamson MaiaKearns PamelaLass GeffenIp-Toma ChristinaLigon JohnLewin JeremyLivingston J AndrewMarchais AntoninMcCabe Martin GMittnacht SybilleNathrath MichaelaPalmerini EmanuelaPantziarka PanPatel SeemaPatel SheenaReed DamonRoberts RyanScotlandi KatiaSlotkin EmilyTseng MandySmallwood WalkerSorensen Poul HValverde ClaudiaWane MadinaWilson Gemma APearson Andrew D JJenkinson DavidGaspar NathalieStrauss Sandra J - The 15-leucine-rich repeat containing membrane protein (LRRC15) is a transmembrane protein derived from the leucine-rich repeat (LRR) superfamily that participates in various cell-cell and cell-extracellular matrix interactions, regulating fibrogenesis, vascular invasion, tumorigenesis, and the formation of the innate immune barrier to drive specific antiviral responses. LRRC15, whose expression is reportedly induced by TGF-β and IL-1β stimulation, was recently found to be associated with the development of skeletal diseases, and its presence has been related to the pathophysiological processes of osteoporosis, osteoarthritis and rheumatoid arthritis. Various transmembrane and intracellular signaling transductions are involved in LRRC15-mediated molecular functions, including integrin, NF-κB, Wnt/β-catenin, etc. Additionally, LRRC15 is considered a novel mesenchymal protein and an important biomarker for the occurrence and development of osteosarcoma. Understanding the role of LRRC15 in the bone, joint and tumor microenvironment will facilitate the development of new therapeutic options-particularly LRRC15-based target therapies-for skeletal diseases. - Source: PubMed
Publication date: 2026/07/24
Lin Zi-HaoHu Zhi-ChaoZhang Chang-QingZhu Zhen-ZhongTang Qian - Inflammatory diseases of connective tissues such as periodontitis and rheumatoid arthritis exhibit localized destruction of matrix collagen and loss of tissue function. These diseases are driven by interconnected signaling pathways that determine disease progression and severity. Both periodontitis and rheumatoid arthritis involve the release of extracellular Vimentin (ECV) from stromal and immune cells at diseased sites, but the processes by which ECV binds to cells and promotes inflammatory signaling are not well defined. Recent data point to several putative ECV receptor proteins, one of which is Leucine-Rich Repeat Containing 15, an orphan receptor and cancer-associated fibroblast marker that contributes to inflammation and matrix destruction. Here, we consider the roles of ECV and LRRC15 in connective tissue diseases and discuss how their interactions may promote matrix destruction. We propose that ECV and LRRC15 signal through β1-integrin/FAK, Wnt/β-catenin, and NF-κB to promote cell adhesion, migration and matrix degradation by local fibroblast and immune cell populations. To obtain further insights into ECV-LRRC15 engagement, we used in silico modelling to predict the most likely binding conformation of the ECV-LRRC15 interaction with MEGADOCK. The most probable model suggests the α-helix region of Vimentin's rod domain near the C-terminal tail engages the extracellular N-terminal region of LRRC15 upstream of its leucine-rich loop, potentially signaling through this interface. In this review, we provide an in-depth overview of the functional links between ECV and LRRC15 and discuss their potential roles as drivers of matrix destruction in periodontitis and rheumatoid arthritis. - Source: PubMed
Publication date: 2026/08/07
Yang Claire XNorouzi MasoudAbovsky MarkJurisica IgorMcCulloch Christopher A - Rheumatoid arthritis (RA) and osteoarthritis (OA) frequently coexist, complicating diagnosis and treatment. The extracellular matrix (ECM) serves as a critical modulator of disease progression, coordinating multilayered matrix degradation and inflammatory cascades in both conditions. This study aims to identify ECM-driven molecular signatures to stratify the risk of RA and OA. - Source: PubMed
Publication date: 2026/08/05
Huang BiaojieHuang YuhanLv RuWang WeikaiHu ZhihaoLi GuiboWei ChenChen XiLi ZhengdongZhang Xue - The tumor microenvironment, particularly the tumor stroma, plays a critical role in tumor progression, immune evasion, and therapeutic resistance. However, its interaction with the immune landscape in rectal cancer (RC) remains incompletely understood. This study aimed to comprehensively characterize the stromal-immune ecosystem associated with the tumor stroma ratio (TSR) in RC and to evaluate its clinical and therapeutic relevance. - Source: PubMed
Publication date: 2026/08/03
Wang QianyuTian NaGuo HanchuanXiang YingshiXiao YiLin GuoleZhang GuannanXu LaiLu JunyangChen GangCai HuiyunDu XiaohuiDu JunfengWu Bin